https://www.selleckchem.com/pr....oducts/methylene-blu
CONCLUSIONS In this secondary analysis of an efficacy outcome from the IMPACT trial, once-daily single-inhaler FF/UMEC/VI triple therapy reduced the risk of ACM versus UMEC/VI in patients with symptomatic COPD and a history of exacerbations. FUNDING GSK(CTT116855/NCT02164513). This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http//creativecommons.org/licenses/by-nc-nd/4.0/).OBJECTIVES To explore the expression of miR-34a and its e
Like
Comment
Share
